Navigation Links
Autism Genome Project delivers genetic discovery
Date:4/24/2014

NEW YORK, N.Y. (April 24, 2014) A new study from investigators with the Autism Genome Project, the world's largest research project on identifying genes associated with risk for autism, has found that the comprehensive use of copy number variant (CNV) genetic testing offers an important tool in individualized diagnosis and treatment of autism.

Funded primarily by Autism Speaks, the world's leading autism science and advocacy organization, the Autism Genome Project involved more than 50 research centers in 11 countries. The report, published today in the American Journal of Human Genetics, delivers on the 10-year project's objective to provide practical methods for earlier diagnosis and personalized treatment of autism.

"With the publication of this study, we should step back to recognize and celebrate the pioneering achievements of the AGP and what they have accomplished in helping to launch the field of genomic risk discovery in autism," says Autism Speaks Chief Science Officer Rob Ring. "The AGP has generated information that holds the potential to guide medical care for certain individuals with autism today. They have demonstrated that science can work for families, and Autism Speaks is proud to have been a supporter of the work all along the way."

The study involved CNV testing of 2,446 families affected by autism and 4,768 individuals unaffected by neurologic or psychiatric disorders. Overall, CNVs were significantly more common in the participating families affected by autism. And, the CNV testing uncovered dozens of cases where autism-linked gene changes were associated with additional health risks warranting medical attention.

In nine of the families affected by autism, CNVs involved a gene that indicates elevated risk for seizures and epilepsy. "This result warrants an immediate referral to a neurologist," explains senior author Stephen Scherer of the Toronto's Hospital for Sick Children and the University of Toronto. Similarly, CNV testing indicated a high risk for muscular dystrophy in several of the autism families and identified syndromes associated with heart problems in others.

CNVs are genetic changes that involve duplication or deletion of entire segments of DNA. They do not typically show up on standard genetic tests which search for "spelling mistakes" in the DNA letters that compose a gene. Those standard tests identify a clear genetic autism link in only 15 to 20 percent of the cases.

"This report and its extensive supplements should become a new guidebook for medical geneticists working with families affected by autism," Dr. Scherer says.

In addition, the study added dozens of genes to the growing list of those that contribute to the development of autism. Surprisingly, the autism genes identified through CNV testing had little overlap with those detected using standard exome gene sequencing, yet researchers say they affect the same brain pathways.

"These gene discoveries will help guide further research on autism subtypes and their treatment," Dr. Scherer says.

In response, the investigators urge medical geneticists to add CNV testing to the standard gene tests for autism and to consult medical recommendations for the many autism-linked syndromes that CNV testing can reveal. CNV testing is currently available, though it's not typically part of standard genetic testing for autism. Whole genome sequencing is the next step in genetic testing for Autism but is not yet widely available in ordinary medical settings. Autism Speaks has taken a world-leadership position in in this direction with its Autism Ten Thousand Genomes (Aut10K) program.


'/>"/>

Contact: Steffanie Marchese
steffanie.marchese@autismspeaks.org
646-345-8537
Autism Speaks
Source:Eurekalert  

Related biology news :

1. Holding a mirror to brain changes in autism
2. Autism risk gene linked to differences in brain structure
3. Autism Speaks awards $1.1 million to fund high priority studies
4. Spontaneous gene glitches linked to autism risk with older dads
5. Gene mutation identified as contributor to autism spectrum disorders
6. Researchers across North America team up to find genetic markers for autism
7. New genes contributing to autism and related neurodevelopmental disorders uncovered
8. Research shows how PCBs promote dendrite growth, may increase autism risk
9. Common genetic variants identify autism risk in high risk siblings of children with ASD
10. MindSpec launches online Autism Reading Room
11. New treatment for irritability in autism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Autism Genome Project delivers genetic discovery
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... National Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, the ... element of grant applications subject to the existing policy. AMIA recommended that NIH ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... with services spanning the full spectrum of drug and device development, and ... to pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) ...
(Date:1/19/2017)... Acupath Laboratories, Inc., a leading provider of ... Executive Committee that will guide the company,s vision and ... Cucci , a 15-year veteran of the anatomic pathology ... to Chief Sales Officer .  Prior to joining ... sales leadership roles at several leading lab industry organizations ...
Breaking Biology Technology: